Clinical trial
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
NCT00834210 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
- Lead sponsor
- Allergan
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- September 30, 2009
- Enrollment
- 171 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.